First US Commercial Appointment: Atlas Genetics Appoints Keith Stauffer As VP Sales & Marketing

BATH, England, November 16, 2015 /PRNewswire/ --

Atlas Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces the appointment of Keith Stauffer as VP Sales and Marketing. Based in the newly opened Boston office, Keith will lead the launch and commercialisation of the Atlas Genetics io® System.

Since 2011, Keith has been VP Marketing for Infectious Diseases at Alere Inc., where most recently he was responsible for developing the pricing strategy, aligning reimbursement initiatives and marketing campaigns for the launch of the Alere i ™ Flu test, the first CLIA waived POC molecular rapid flu test. In the first 12 months from launch over 2,500 instruments were placed. Previously, Keith was VP Sales for the Clinical Products Group within Alere, which included infectious disease POC tests. Prior to Alere, Keith worked for Thermo Electron in their Point of Care and Rapid Diagnostics division.

John Clarkson, CEO, said: "We are delighted to welcome Keith to Atlas Genetics. With CE mark approval for our first test anticipated around the end of this year we are about to enter the next phase in the growth of the Company. Keith's expertise in the development and roll-out of commercialisation strategies within this field will be invaluable as we bring our ultra-rapid point of care tests for Sexually Transmitted Infections and Hospital Acquired Infections to market."

Keith Stauffer, VP Sales & Marketing, added: "The io® System developed by Atlas Genetics offers a unique solution to the delivery of high quality testing results at the point of care. I believe that this system will transform the treatment and management of patients with infectious diseases across a range of clinical areas and I look forward to working with John and his team to launch the io® System in Europe and the US."

NOTES TO EDITORS

Atlas Genetics Ltd (http://www.atlasgenetics.com )

Atlas Genetics develops ultra-rapid point-of-care (POC) diagnostic tests for infectious diseases. The Atlas Genetics io® System uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability. The Company has its head office and R&D facilities near Bath in the UK, with a commercial office in Boston, USA.

Contact details:
Atlas Genetics Ltd:
Tel: +44(0)1225-717930

John Clarkson
FTI Consulting:
Tel: +44(0)20-3727-1000
Mo Noonan / Matthew Moss

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.